Cost Plus Drugs Expands to Rare Disease Treatments
A Dallas-based factory is now utilizing specialized DNA-like molecules to create custom rare disease medicines.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you believe private companies can successfully lower the cost of rare disease treatments?
In 2026, Cost Plus Drugs transitioned a portion of its Dallas manufacturing facility to produce custom treatments for rare diseases. The new process involves creating specialized molecules designed to target specific genetic mutations in individual patients.
Why it matters
The initiative aims to improve treatment accessibility for patients suffering from rare conditions who have historically faced limited medical options. This shift represents a new chapter for the company, which previously focused on manufacturing generic chemotherapy and antifungal medications.
The Dallas facility processes DNA-like molecules to manufacture custom medicines tailored to specific genetic mutations. This capability contrasts with the company's prior focus on manufacturing generic chemotherapy and antifungal medications.
The players
Cost Plus Drugs
This company is a pharmaceutical firm known for its efforts to reduce costs for patients by manufacturing and distributing generic and custom medications.
Mark Cuban
He is a prominent entrepreneur and investor who has dedicated his business efforts toward improving affordability and access within the pharmaceutical industry.
The details
Chemists in California and researchers in the Netherlands collaborate to develop the unique treatment molecules that are then manufactured at the Dallas site. These custom drugs are engineered to address the specific needs of patients with rare diseases, moving beyond the company's traditional generic drug model.
Timeline
From 2021 to 2026, Mark Cuban worked to lower the costs of generic medications.
Custom rare disease medicines began arriving at the Dallas factory in 2026.
The Tech Race
This transition marks a significant shift toward personalized genetic mutation therapy within the pharmaceutical sector. It moves the company away from mass-produced generic medications and into the complex, precision-based arms race of modern biotech manufacturing.
Patients with rare diseases may see improved access to custom-tailored therapies that were previously difficult to obtain. This manufacturing shift aims to reduce the barriers between complex genetic research and the actual delivery of patient-specific treatments.
The takeaway
The move toward custom medicine highlights how manufacturing technology is becoming increasingly specialized to serve smaller patient populations. Patients and healthcare providers should monitor how this facility scales production to determine if these treatments could become a standard option for rare conditions.
Further reading
For more on industry developments, visit the Biotech section.
Source note: This article includes information reported by STAT.
Live Poll
Do you believe private companies can successfully lower the cost of rare disease treatments?
